Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo-PrP binding and downstream pathways.

Amyloid β oligomers (Aβo) are the main toxic species in Alzheimer's disease, which have been targeted for single drug treatment with very little success. In this work we report a new approach for identifying functional Aβo binding compounds. A tailored library of 971 fluorine containing compounds was selected by a computational method, developed to generate molecular diversity.